A randomized, controlled, multicenter, phase III IGNYTE-3 trial (NCT06264180) is currently underway to evaluate the efficacy of RP1 in combination with nivolumab in patients with relapsed or refractory metastatic or locally advanced unresectable melanoma who have previously received the combination of anti-CTLA4 and anti-PD-1, and BRAF-directed treatment (in patients with BRAF mutated melanoma), or who are ineligible for anti-CTLA-4 treatment [91]. This evidence concerns the gene BRAF and melanoma.